NRX Pharmaceuticals, Inc. Annual Operating Income (Loss) in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
NRX Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2023.
  • NRX Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.02M, a 48% increase year-over-year.
  • NRX Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$20.5M, a 38.5% increase year-over-year.
  • NRX Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$27.8M, a 37.2% increase from 2022.
  • NRX Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$44.3M, a 61.7% increase from 2021.
  • NRX Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$116M, a 125% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$27.8M +$16.5M +37.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-29
2022 -$44.3M +$71.5M +61.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 -$116M -$64.4M -125% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$51.4M -$50.7M -7105% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$713K +$293K +29.1% Jan 1, 2019 Dec 31, 2019 10-K/A 2021-05-14
2018 -$1.01M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.